EGFR and non-small cell lung carcinoma: [6] Given the heterogeneity of NSCLC and potential crosstalk between signaling pathways implicated in tumor growth, angiogenesis and metastasis, combining targeted agents could improve the efficacy over single-target agents,, which could also be necessary to reverse resistance to EGFR inhibitor therapy.